Showing results (61-70 of 156) with videos related to
Sort By:
Pageof 16
Frontiers in Pharmacology|February 10, 2023
Understanding the role of the gut microbiome in gastrointestinal cancer: A reviewDuygu Ağagündüz, Ermelinda Cocozza, Özge Cemali, et al.Critical Reviews in Oncology/Hematology|November 21, 2021
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?Amelia Insa, Paloma Martín-Martorell, Raimondo Di Liello, et al.Frontiers in Pharmacology|August 14, 2025
Correction: Understanding the role of the gut microbiome in gastrointestinal cancer: A reviewDuygu Agagündüz, Ermelinda Cocozza, Özge Cemali, et al.Journal of Cellular Physiology|April 3, 2008
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cellsTina Cascone, Maria Pia Morelli, Floriana Morgillo, et al.Oncology Letters|January 21, 2017
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature reviewMorena Fasano, Carminia Maria Della Corte, Giovanni Vicidomini, et al.Diabetes Research and Clinical Practice|January 20, 2020
Metformin: An old drug against old age and associated morbiditiesTeresa Salvatore, Pia Clara Pafundi, Floriana Morgillo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2013
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell linesFloriana Morgillo, Ferdinando Carlo Sasso, Carminia Maria Della Corte, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2015
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with CetuximabStefania Napolitano, Giulia Martini, Barbara Rinaldi, et al.Expert Review of Anticancer Therapy|February 11, 2023
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systemsStefano Lucà, Giuseppa Zannini, Floriana Morgillo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2015
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft ModelsTeresa Troiani, Stefania Napolitano, Giulia Martini, et al.Pageof 16